Episode 5
Episode 4. Measurable Residual Disease in AML
In this episode, we discuss the techniques to assess measurable residual disease (MRD) in AML, clinical implications of MRD results, and future directions on MRD-guided patient management.
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
August 24, 20221h 2m
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/
Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006
Topics
HematologyCancer